Brainstorm Cell Therapeutics | BCLI - Sales Revenues

Stock Price
0.85
Daily Change
-0.02 -1.73%
Monthly
-5.56%
Yearly
6.92%
Q2 Forecast
0.90

Brainstorm Cell Therapeutics reported 0 in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Biogen USD 2.28B 250M Dec/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 67.33M 65.44M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Grifols EUR 2.34B 33.3M Mar/2026
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Mesoblast USD 30.3M 17.1M Dec/2025